Edition:
United States

Sanofi SA (SNY.N)

SNY.N on New York Stock Exchange

40.49USD
9:55am EST
Change (% chg)

$0.72 (+1.81%)
Prev Close
$39.77
Open
$40.21
Day's High
$40.49
Day's Low
$40.21
Volume
50,980
Avg. Vol
253,787
52-wk High
$44.50
52-wk Low
$36.82

SNY.N

Chart for SNY.N

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $102,764.70
Shares Outstanding(Mil.): 2,578.86
Dividend: 1.66
Yield (%): 4.18

Financials

  SNY.N Industry Sector
P/E (TTM): 23.23 29.74 30.35
EPS (TTM): 1.71 -- --
ROI: -- 15.90 15.27
ROE: -- 17.00 16.60

EU regulator accepts Sanofi/Regeneron's Dupixent product for review

PARIS The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday.

Dec 08 2016

Sanofi exploring bid for Actelion amid J&J talks: Bloomberg

French drugmaker Sanofi is considering a bid for Swiss biotech company Actelion , rivaling an offer made by U.S. healthcare company Johnson & Johnson , Bloomberg reported.

Dec 06 2016

Novo, Sanofi go head to head as FDA clears new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Nov 22 2016

UPDATE 2-Novo, Sanofi go head to head as FDA clears new diabetes drugs

* Companies to sell two-drug products at discount (Adds detail on pricing, quote from Novo Nordisk executive)

Nov 22 2016

BRIEF-Sanofi sees Soliqua costing about same as a GLP-1 drug in U.S.

* Says expects daily wholesale acquisition cost of new diabetes drug Soliqua will be similar to daily price of a GLP-1 in U.S.

Nov 22 2016

BRIEF-Zealand Pharma: US FDA approves Soliqua 100/33 for treatment of adults with type 2 diabetes

* Said on Tuesday, U.S. FDA approves Soliqua 100/33 for treatment of adults with type 2 diabetes

Nov 22 2016

No early win for Sanofi, Regeneron cholesterol drug in study

Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

Nov 17 2016

UPDATE 1-No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

Nov 17 2016

No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent.

Nov 17 2016

France sets up fund for Sanofi epilepsy drug victims

PARIS France is setting up a fund to meet compensation claims from people affected by an epilepsy treatment made by Sanofi that is believed to cause birth malfunctions and slow neurological development.

Nov 16 2016

Competitors

Earnings vs. Estimates